Irbesartan Zentiva

Irbesartan, the active ingredient in Irbesartan Zentiva, is a angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and helps protect kidney function in patients with type‑2 diabetes, and belongs to the class of antihypertensive agents indicated for blood pressure control.

GNH USA supplies Irbesartan Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global markets, and timely delivery to meet patient care needs worldwide.

Irbesartan is an angiotensin II receptor blocker used to manage conditions related to high blood pressure and renal protection.

Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. Diabetic nephropathy: slows progression of kidney disease in type‑2 diabetes patients. Proteinuria in diabetic kidney disease: reduces urinary protein excretion, supporting renal function.

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Fatigue - Cough - Hyperkalaemia - Abdominal pain

Serious or Rare Side Effects: - Angioedema - Acute renal impairment - Severe hypotension - Hepatic injury - Neutropenia - Myocardial infarction

Before prescribing Irbesartan, consider the following precautions to ensure safe use.

Renal function: assess baseline creatinine and monitor periodically. Electrolytes: check potassium levels, especially in patients on potassium‑sparing diuretics. Pregnancy: contraindicated in second and third trimester due to fetal toxicity. Concurrent ACE inhibitor or ARB therapy: avoid combination to prevent renal failure. Hypotension: monitor blood pressure after initiation, especially in volume‑depleted patients. Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Irbesartan can interact with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Concomitant use with ACE inhibitors or other ARBs: risk of severe hypotension, hyperkalaemia, renal failure. - Potassium‑supplementing agents or potassium‑sparing diuretics: may cause dangerous hyperkala